Current:Home > Contact-usAn experimental Alzheimer's drug outperforms one just approved by the FDA-LoTradeCoin
An experimental Alzheimer's drug outperforms one just approved by the FDA
View Date:2024-12-23 19:48:58
Patients in the early stages of Alzheimer's may soon have a new option to stave off the loss of memory and thinking.
In a study of more than 1,700 people, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%, scientists reported at the Alzheimer's Association International Conference in Amsterdam.
The result, published simultaneously in the journal JAMA, suggests that donanemab is at least as effective as the newly approved drug Leqembi (lecanemab), which was found to reduce progression by about 27%.
"This is the biggest effect that's ever been seen in an Alzheimer's trial for a disease-modifying drug," says Dr. Daniel Skrovonsky, director of research and development at Eli Lilly, which makes donanemab.
The company has submitted the results to the Food and Drug Administration and expects a decision by the end of the year.
But experts caution that donanemab is no cure, and that its benefit amounts to only about a seven-month delay in the loss of memory and thinking.
"I do think that will make a difference to people," says Dr. Reisa Sperling, who directs the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital in Boston. "But we have to do better."
Early treatment is key
Donanemab, like Leqembi, is a monoclonal antibody designed to remove a substance called beta-amyloid from the brain. Beta-amyloid tends to form sticky plaques in the brains of people with Alzheimer's.
The donanemab study focused on people whose brain scans showed plaques and other changes associated with early Alzheimer's. They had only mild cognitive symptoms.
Even within that group, though, people with more advanced disease saw less benefit from the drug.
"What we saw is that the ability to slow disease progression is strongest if you catch this disease earlier," Skrovonsky says.
The study also suggests that patients may not need monthly intravenous infusions of donanemab for life.
Patients were taken off the drug once the plaques in their brains were mostly gone, usually within a year. The plaques did not reappear during the 18-month study, and the benefit to memory and thinking continued.
That appears to give donanemab an edge over Leqembi, which requires ongoing treatment. But it's still not clear whether donanemab's benefits will persist for years after treatment ends.
"I imagine in the future we'll have this initiation phase where we knock down plaque and then we'll have maintenance therapy," Sperling says.
Both donanemab and Leqembi can cause dangerous swelling or bleeding in the brain.
In the donanemab study, brain scans revealed this side effect in about 25% of patients. About 6% had symptoms, like headache, nausea, and confusion. Three patients died.
A new era for Alzheimer's treatment?
The results with both donanemab and Leqembi provide strong evidence that removing amyloid from the brain can slow down Alzheimer's. That approach, known as the amyloid hypothesis, had been in doubt after dozens of other amyloid drugs failed to help patients.
One reason for the recent success is earlier treatment, Sperling says. Instead of treating patients who've already sustained significant brain damage from Alzheimer's, researchers have focused on people whose brains are still relatively healthy.
Another factor is the way researchers are approaching treatment, Sperling says.
"We've learned to be more aggressive with dosing," she says, which quickly reduces amyloid to very low levels in the brain.
But scientists still aren't sure which forms of amyloid offer the best target.
Single amyloid molecules appear to be harmless. But scientists have learned that when these molecules begin to clump together, they can take on forms that are toxic. Eventually, these clumps end up in plaques between brain cells.
"There's been a debate in our field for 30 years now about whether the plaques themselves are causing the problem," Sperling says. And the results with donanemab and leqembi are unlikely to end that debate.
Donanemab is designed to target plaques specifically. Leqembi is designed to target other forms of amyloid, though it also removes plaques.
Yet both drugs appear to slow down the loss of memory and thinking, in patients with early Alzheimer's.
A study Sperling is involved in could help answer the amyloid question by treating people who still have very little plaque in their brains.
"If we see benefit even at that stage," Sperling says, "one might argue it's not just plaque" eroding memory and thinking.
veryGood! (81963)
Related
- AIT Community Introduce
- Young Thug trial judge removed over allegations of 'improper' meeting
- Horoscopes Today, July 15, 2024
- Hamas says Gaza cease-fire talks haven't paused and claims military chief survived Israeli strike
- Jennifer Lopez Turns Wicked Premiere Into Family Outing With 16-Year-Old Emme
- Untangling Christina Hall's Sprawling Family Tree Amid Josh Hall Divorce
- Swap Sugary Drinks for a 33% Discount on Poppi Prebiotic Soda Before Amazon Prime Day 2024 Ends
- 2024 British Open tee times: When do Tiger Woods, Rory McIlroy tee off?
- Beyoncé's Grammy nominations in country categories aren't the first to blur genre lines
- CONMEBOL blames Hard Rock Stadium for unruly fans, ugly scenes before Copa America final
Ranking
- After years of unrest, Commanders have reinvented their culture and shattered expectations
- 75-year-old man missing for 4 days found alive by K-9 in Maine bog
- The nation's 911 system is on the brink of its own emergency
- James Webb telescope photos show the Penguin and Egg galaxies in greater detail
- South Carolina does not set a date for the next execution after requests for a holiday pause
- More thunderstorms expected Tuesday after storms clobber Midwest, tornado confirmed
- Republican convention focuses on immigration a day after a bandaged Trump makes triumphant entrance
- Spain clinches record 4th European Championship title, beating England 2-1
Recommendation
-
When do new 'Yellowstone' episodes come out? Here's the Season 5, Part 2 episode schedule
-
Tesla's Cybertruck outsells Ford's F-150 Lightning in second quarter
-
Creature that washed up on New Zealand beach may be world's rarest whale — a spade-toothed whale
-
What is Demolition Ranch, the YouTube channel on Thomas Matthew Crooks' shirt?
-
Tech consultant testifies that ‘bad joke’ led to deadly clash with Cash App founder Bob Lee
-
Kirby Smart again addresses Georgia football players driving arrests at SEC media days
-
Emma Roberts Engaged to Actor Cody John: See Her Ring
-
BBC Journalist John Hunt Speaks Out After Wife, Daughters Are Killed in Crossbow Attack